RT Journal Article
T1 The Five “Ws” of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When
A1 González Gascón y Marín, Isabel
A1 Ballesteros Andrés, Mónica
A1 Martínez Flores, Sara
A1 Rodríguez Vicente, Ana Eugenia
A1 Pérez Carretero, Claudia
A1 Quijada Álamo, Miguel
A1 Rodríguez Sánchez, Alberto
A1 Hernández Rivas, José Ángel
AB Chronic lymphocytic leukemia (CLL) is a disease of the elderly, but chronological age does not accurately discriminate frailty status at the inter-individual level. Frailty describes a person’s overall resilience. Since CLL is a stressful situation, it is relevant to assess the patient´s degree of frailty, especially before starting antineoplastic treatment. We are in the era of targeted therapies, which have helped to control the disease more effectively and avoid the toxicity of chemo (immuno) therapy. However, these drugs are not free of side effects and other aspects arise that should not be neglected, such as interactions, previous comorbidities, or adherence to treatment, since most of these medications are taken continuously. The challenge we face is to balance the risk of toxicity and efficacy in a personalized way and without forgetting that the most frequent cause of death in CLL is related to the disease. For this purpose, comprehensive geriatric assessment (GA) provides us with the opportunity to evaluate multiple domains that may affect tolerance to treatment and that could be improved with appropriate interventions. In this review, we will analyze the state of the art of GA in CLL through the five Ws.
PB MDPI
SN 2072-6694
YR 2023
FD 2023
LK https://hdl.handle.net/20.500.14352/103464
UL https://hdl.handle.net/20.500.14352/103464
LA eng
NO Instituto de Salud Carlos III
NO Junta de Castilla y León
NO Fundación Mutua Madrileña
NO Red Temática de Investigación Cooperativa en Cáncer
NO Centro de Investigación Biomédica en Red de Cáncer
NO Fundación Española de Hematología y Hemoterapia
DS Docta Complutense
RD 19 ene 2026